<DOC>
	<DOC>NCT00442871</DOC>
	<brief_summary>The main purpose of this study is to compare how one 50 mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe kidney problems. The study is also being done to 1) check on how well the study drug is tolerated by healthy subjects versus those with liver problems and 2) to check if liver impairment affects how the study drug binds to protein in the blood.</brief_summary>
	<brief_title>Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
	<criteria>Healthy or have renal impairment Females (the following requirement applies only if able to have children): agree to doctor approved birth control methods, or partner has had a vasectomy Negative drug, alcohol, and HIV tests. Taking a medication or therapy not approved by the study doctor Rapidly changing kidney function Drug or alcohol abuse within past 6 months Used an investigational drug in the past 30 days Females who are pregnant or nursing Have active hepatitis B or C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Renal Impairment,</keyword>
	<keyword>chronic immune thrombocytopenia purpura,</keyword>
	<keyword>thrombocytopenia,</keyword>
	<keyword>chemotherapy induced thrombocytopenia</keyword>
</DOC>